138 related articles for article (PubMed ID: 33766703)
1. Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial.
Armstrong S; Brown S; Stancliffe M; Ostler P; Hughes R; Hoskin P; Alonzi R
Radiother Oncol; 2021 Jun; 159():67-74. PubMed ID: 33766703
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
3. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
5. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.
Alayed Y; Loblaw A; McGuffin M; Chung HT; Tseng CL; D'Alimonte L; Cheung P; Liu S; Chu W; Szumacher E; Helou J; Ravi A; Haider M; Mamedov A; Zhang L; Morton G
Radiother Oncol; 2021 Jan; 154():29-35. PubMed ID: 32918971
[TBL] [Abstract][Full Text] [Related]
6. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
[TBL] [Abstract][Full Text] [Related]
7. MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.
Alayed Y; D'Alimonte L; Helou J; Ravi A; Morton G; Chung HT; Haider M; McGuffin M; Zhang L; Loblaw A
Radiother Oncol; 2019 Dec; 141():144-148. PubMed ID: 31564554
[TBL] [Abstract][Full Text] [Related]
8. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
9. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
Mendez LC; Ravi A; Chung H; Tseng CL; Wronski M; Paudel M; McGuffin M; Cheung P; Loblaw A; Morton G
Brachytherapy; 2018; 17(2):291-297. PubMed ID: 29137956
[TBL] [Abstract][Full Text] [Related]
10. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
[TBL] [Abstract][Full Text] [Related]
11. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone?
Galalae RM; Zakikhany NH; Geiger F; Siebert FA; Bockelmann G; Schultze J; Kimmig B
Brachytherapy; 2014; 13(2):117-22. PubMed ID: 24360880
[TBL] [Abstract][Full Text] [Related]
12. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
[TBL] [Abstract][Full Text] [Related]
13. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
14. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
[TBL] [Abstract][Full Text] [Related]
16. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
[TBL] [Abstract][Full Text] [Related]
18. Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients.
Agoston P; Major T; Fröhlich G; Szabó Z; Lövey J; Fodor J; Kásler M; Polgár C
Brachytherapy; 2011; 10(5):376-84. PubMed ID: 21345741
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.
Chapman CH; Braunstein SE; Pouliot J; Noworolski SM; Weinberg V; Cunha A; Kurhanewicz J; Gottschalk AR; Roach MI; Hsu IC
J Contemp Brachytherapy; 2018 Jun; 10(3):193-201. PubMed ID: 30038638
[TBL] [Abstract][Full Text] [Related]
20. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial.
Gomez-Iturriaga A; Buchser D; Mayrata E; San Miguel I; Gonzalez A; Suarez F; Martinez-Indart L; Minguez P; Espinosa J; Perez F; Cacicedo J; Casquero F
Radiother Oncol; 2020 May; 146():16-20. PubMed ID: 32086047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
